Cardiac hypertrophy and dilatation can result from stimulation of signal transduction pathways mediated by heterotrimeric G proteins, especially G q , whose ␣ subunit activates phospholipase C␤ (PLC␤). We now report that transient, modest expression of a hemagglutinin (HA) epitope-tagged, constitutively active mutant of the G q ␣ subunit (HA␣* q ) in hearts of transgenic mice is sufficient to induce cardiac hypertrophy and dilatation that continue to progress after the initiating stimulus becomes undetectable. At 2 weeks, HA␣ * q protein is expressed at less than 50% of endogenous ␣ q͞11 , and the transgenic hearts are essentially normal morphologically. Although HA␣ * q protein declines at 4 weeks and is undetectable by 10 weeks, the animals develop cardiac hypertrophy and dilatation and die between 8 and 30 weeks in heart failure. As the pathology develops, endogenous ␣ q͞11 rises (2.9-fold in atria; 1.8-fold in ventricles). At 2 weeks, basal PLC activity is increased 9-to 10-fold in atria but not ventricles. By 10 weeks, it is elevated in both, presumably because of the rise in endogenous ␣ q͞11 . We conclude that the pathological changes initiated by early, transient HA␣ * q expression are maintained in part by compensatory changes in signal transduction and other pathways. 
Many kinds of stresses can lead to cardiac hypertrophy and dilatation; some are mechanical, others are the result of stimulation of signal transduction pathways mediated by heterotrimeric G proteins, especially G q , whose ␣ subunit stimulates phospholipase C␤ (PLC␤). For example, activation of receptors that are coupled to G q (such as receptors for endothelin, angiotensin II, and ␣ 1 -adrenergic agonists) leads to hypertrophy in isolated neonatal cardiomyocytes (reviewed in ref. 1) and in vivo (2) (3) (4) . Although each of these receptors activates G␣ q , the hypertrophic phenotype differs among the different models in age of onset, severity, chamber-specificity, and histology. Some of the variation may be the result of receptors coupling to more than one G protein and initiating several signaling pathways. The importance of G␣ q is emphasized further by the observation that interfering with the interface between G q -coupled receptors and G␣ q by overexpressing a carboxyl-terminal peptide of G␣ q in hearts of transgenic mice caused the mice to develop significantly less hypertrophy in response to pressure overload (5) . While the present work was in progress, D'Angelo et al. (6) reported that a 4-fold increase in the expression of wild-type G␣ q in the mouse heart led to cardiac hypertrophy at 12-14 weeks. The authors carefully described the cardiac function of transgenic hearts by echocardiography and hemodynamic studies. However, the previous studies have not reported whether continuous transgene expression is necessary for the development and progression of cardiac pathology.
We now report that transient, modest cardiac expression of a hemagglutinin (HA) epitope-tagged, constitutively active mutant of the G q ␣ subunit (HA␣* q ) in transgenic mice is sufficient to cause hypertrophy and dilatation both of atria and ventricles that proceed inexorably to death in cardiac failure. While it is not unusual for short but complex stimuli (for example, myocardial infarction) to lead to progressive cardiac pathology, it has not been shown previously that transient expression of a single protein can do so. The internally placed HA epitope does not interfere with HA␣* q function (7) , but enabled us to distinguish transgenic HA␣* q from endogenously expressed ␣ q and to determine the time course of its expression. The mutant protein has diminished GTPase activity, so it remains in its active, GTPbound state and does not depend on receptor-mediated activation (8) . Therefore, it should be effective at a low level of expression. Furthermore, since HA␣* q interacts poorly with G protein ␤␥ subunits, it is unlikely to bind to endogenous ␤␥ subunits and therefore shift the equilibrium of other ␣ subunits to the dissociated, active state.
Recently, Molkentin et al. (9) demonstrated that calcineurin, a Ca 2ϩ -activated phosphatase, regulates cardiac hypertrophy in mice through activation of NFAT (nuclear factor of activated T cells), which then binds to GATA, forming a transcription factor that may control the hypertrophic gene response. Mice expressing an active form of calcineurin had a 2-to 3-fold increase of heart weight͞body weight ratios compared with control littermates. However, treatment with cyclosporin A (CsA) prevented hypertrophy, presumably through inhibition of calcineurin and prevention of the dephosphorylation of NFAT. Because HA␣* q acts upstream of calcineurin, activating additional signaling pathways (such as protein kinase C), we expected that CsA treatment might blunt some effects of HA␣* q expression, but not prevent the cardiac pathology. Indeed, our results suggest that pathways in addition to activation of calcineurin may contribute to the development of the hypertrophic, dilated phenotype initiated by HA␣* q .
tively active G protein ␣ q subunit (HA␣ q Q209L or HA␣* q ) was kindly provided by Paul T. Wilson and Henry R. Bourne (University of San Francisco, CA). A pGEM-9Zf vector containing the murine 5.5-kb ␣-myosin heavy chain promoter and the simian virus 40 (SV40) intron͞polyadenylation signal (0.85 kb) were the gift of Walter J. Koch (Duke University Medical Center, Durham, NC). The 1.1-kb HindIII-NotI fragment containing the coding sequence for HA␣* q was ligated into the blunted SalI sites of pGEM-9Zf and confirmed by restriction mapping and nucleotide sequencing. A linear 7.45-kb DNA fragment was released with KpnI and NotI. Transgenic FVB mice were generated by the Transgenic Mouse Facility of Harvard Medical School. The transgene was identified by PCR with transgene-specific primers and by genomic Southern analysis using a random-primed 32 Plabeled DNA probe consisting of part of the SV40 intron sequence (750 bp). We used strain ␣* q 52.
Histology. Hearts were fixed in 4% neutral-buffered formalin or 0.1 M cacodylate-buffered 2.5% glutaraldehyde͞2% paraformaldehyde at pH 7.4 (Karnovsky fixative), cut either transversely at the midventricular level or bisected in a plane that exposed both atria and ventricles, and embedded in paraffin. Sections were made from the cut surfaces at 4-5 m and stained with the hematoxylin and eosin stain for overall morphology and Massons' trichrome stain for collagen.
Northern Blot Analysis. Total RNA from ventricles of ␣* q 52 and wild-type littermates was extracted with RNAzol B (Tel-Test, Friendswood, TX). Total RNA (5-10 g) was size-fractionated and blotted by using standard techniques. cDNA probes consisting of part of the SV40 intron sequence (750 bp), rat atrial natriuretic factor (ANF, base pair 1-580; kindly provided by Christine E. Seidman, Harvard Medical School, Boston, MA), or human glyceraldehyde-3-phosphate dehydrogenase (GAPDH, CLONTECH) were random-primed Blots were prehybridized in 50% formamide͞10ϫ Denhardt's solution͞1% SDS͞5ϫ SSC (20ϫ SSC: 3 M NaCl͞0.3 M sodium citrate dihydrate)͞100 g/ml salmon sperm DNA, and hybridized with 3 ϫ 10 6 cpm͞ml of cDNA probes or 3 ϫ 10 7 cpm͞ml of oligonucleotide probes. After two washes each with 1ϫ SSC͞ 0.1% SDS and 0.25ϫ SSC͞0.1% SDS for 15 min at room temperature, followed by a 10 min wash at 55°C with 0.25ϫ SSC͞0.1% SDS (cDNA probes) or 0.5ϫ SSC͞0.1% SDS (oligonucleotide probes), the blots were exposed to x-ray film at Ϫ70°C.
Western Blot Analysis. Hearts were obtained from ␣* q 52 and wild-type littermates at 14-16 days, 30 days, and 62-75 days (designated as 2, 4, and 10 weeks, respectively). Atrial appendages and ventricles were isolated and quickly frozen in liquid nitrogen. On the day of homogenization, left and right atria from 8-10 2-week-old wild-type or ␣* q 52 mice were pooled. Only right atria from 10-week-old mice were pooled (eight wild-type mice and two to three ␣* q 52 mice), since the left atrium often contained thrombi. The heart tissue was homogenized on ice in 50 mM Tris⅐HCl, pH 7.6͞6 mM MgCl 2 ͞75 mM sucrose͞1 mM DTT͞1 mM EDTA plus proteinase inhibitors (3 mM benzamidine and 1 g͞ml each soya and lima bean trypsin inhibitor and leupeptin). Particulate and soluble fractions were separated by ultracentrifugation at 48,500 ϫ g for 30 min at 4°C. The pellet was resuspended with a glass-teflon Potter-Elvehjem tissue grinder. The protein was determined by Bradford assay (11) with BSA as standard.
Seventy-five micrograms of protein from both fractions was separated on 9% SDS͞PAGE (12), followed by wet blotting (13) . Nitrocellulose strips were blocked with 5% nonfat dry milk in PBS, incubated with 12CA5 recognizing the HA epitope (1:1,000, Babco) and C-19 recognizing G␣ q͞11 (1: (14) . Small pieces (1-3 mg) of left and right atria and of the free right ventricular wall from 2-and 10-week-old ␣* q 52 and wild-type littermates were quickly prepared, blotted, weighed, and placed into a 24-well culture dish with 500 l oxygenated (95% O 2 ͞5% CO 2 ) Krebs-Henseleit buffer containing 118 mM NaCl͞4.7 mM KCl͞3 mM CaCl 2 ͞1.2 mM KH 2 PO 4 ͞25 mM NaHCO 3 ͞1.2 mM MgSO 4 ͞0.5 mM EDTA͞10 mM glucose. After 1.5 hr of labeling with 4 Ci͞ml myo[ (15) . The amount of protein in each tissue piece was determined according to Bradford (11) after solubilization of the extracted tissue in 0.5 M NaOH. The results were the same whether referred to mg protein or tissue wet weight. All tissue pieces were viable since, in agreement with ref. 14, they were able to respond to carbamylcholine with a 3-to 5-fold increase in PLC activity (data not shown).
Treatment with CsA. Beginning at 17-18 days of age, pups in two litters each (containing ␣* q 52 mice and wild types) were injected twice daily s.c. in the back of the neck with either CsA (15 mg͞kg body weight) or vehicle (Cremophor EL and ethanol in PBS). The body weight of all mice was monitored every other day. At 43-45 days, mice were sacrificed, hearts and lungs were weighed, and the apex of the ventricles was quickly frozen in liquid nitrogen for subsequent RNA analysis. The right tibia of each mouse was isolated and the length was measured.
To demonstrate the efficiency of CsA treatment, Ca 2ϩ -induced NFAT-1͞p dephosphorylation was studied in Western blots of whole spleen cell lysates from CsA-treated mice compared with control mice. Spleens were removed from animals sacrificed 5 hr after the last injection, placed in ice-cold DMEM (supplemented with 10 mM L-glutamine and 10% fetal calf serum), and dissociated by using a 70-m mesh nylon cell strainer. Cells were counted immediately, adjusted to 10 ϫ 10 
RESULTS
Production of Transgenic Mice. Transgenic mice were created that express a HA epitope-tagged, constitutively active mutation of ␣ q , HA␣* q , under the control of the ␣-MHC promoter (Fig. 1) . Replacing amino acids 125-130 in ␣ q with part of the HA epitope, does not interfere with its function (7) . The ability of the ␣-MHC promoter to drive cardiac-specific transgene expression has been well established (for example, refs. 2 
and 4). This promoter is
In this study, left and right atrial appendages were used. They are referred to as left and right atria. (1998) active throughout development in the atria and turns on around birth in the ventricle (17, 18) . Two independent transgenic lines (␣* q 44 and ␣* q 52) were established from two male founders. The analyses in this report focus on the development of hypertrophy in the ␣* q 52 line. Mice from the ␣* q 44 line express low levels of HA␣* q mRNA and only begin to reexpress ventricular ANF at 5 months of age, whereas ␣* q 52 mice die between 2 and 7 months with massive cardiac dilatation and hypertrophy (see below). Cardiac Pathology in ␣* q 52 Mice. At 2 weeks, the hearts from ␣* q 52 mice were essentially normal and barely distinguishable from wild types. The ventricular weight͞body weight (VW͞BW) ratio in ␣* q 52 mice compared with wild-type mice was only slightly increased ( Table 1 ). The atrial weight͞body weight (AW͞BW) ratio was not changed significantly (Table 1) , although there was a suggestion of mild, variable atrial enlargement ( Fig. 2A) . No consistent pathologic findings were noted upon histological examination of any chamber (not shown). By 4 weeks, the AW͞BW and VW͞BW ratios were increased, and by 10 weeks, ␣* q 52 mice revealed massive enlargement and dilatation of all four chambers ( Fig. 2 A and C) . Histological examination showed atrial thrombi in various stages of organization. The atria were dilated with wall thinning and fibrosis ( Fig. 2 D and F, respectively) . Since there were often thrombi in the left atria, the degree of hypertrophy is better reflected by the VW͞BW ratio that was increased to 121% of wild type ( Table 1 ). The cardiomyocytes of the hypertrophied, dilated ventricles were enlarged with big hyperchromatic nuclei and degenerative changes (including intracellular vacuolization) (Fig. 2H ). There was diffuse interstitial fibrosis ( Fig. 2 J) , but no evidence of myocyte disarray, necrosis, or myocarditis. Similar to our model, expression of unactivated G␣ q (6), ␣ 1 -adrenergic receptors (2), or angiotensin AT 1 receptors (4) caused cardiomyopathy with myocyte hypertrophy and vacuolization without myocyte disarray or necrosis. In contrast, we observed diffuse atrial and ventricular fibrosis, not reported in those studies. The ␣* q 52 mice died spontaneously between 8 and 30 weeks of age, often with pulmonary congestion reflected in an increased lung weight͞body weight ratio (Table 1 ). There was intense hepatic congestion in some mice, occasionally with early centrolobular necrosis (not shown), indicating bilateral cardiac dysfunction. No organ infarcts were detectable in autopsies, suggesting that the deaths were not caused by thromboemboli. HA␣ * q Transgene Is Transiently Expressed at a Low Level. HA␣ * q protein, detected with antibody against the HA epitope, was present in the particulate fraction of atrial appendages and ventricles of 2-week-old ␣* q 52 mice (Fig. 3A) . No HA␣* q was found in the soluble fraction (data not shown). By 4 weeks, the level of HA␣ * q dropped in ventricles to 28 Ϯ 8% (SEM, n ϭ 5, P Ͻ 0.001) of the level at 2 weeks. By 10 weeks, HA␣* q protein was undetectable in atria and in ventricles. At 2 weeks, total ␣ q͞11 (endogenous ␣ q͞11 plus HA␣* q ) was increased in the particulate fraction from atria by 30 Ϯ 3% (range, n ϭ 2 pools of left and right atria from 8-10 mice) compared with wild type and in ventricles by 56 Ϯ 15% (SEM, n ϭ 8, P Ͻ 0.02) compared with wild type. Although we cannot ascribe all of the increase in total ␣ q͞11 to transgene expression, these data set an upper limit for the ratio of HA␣ * q to endogenous ␣ q͞11 at 2 weeks. Surprisingly, by 10 weeks, there were major compensatory changes in the level of endogenous ␣ q͞11 . Compared with control, endogenous ␣ q͞11 was increased by 82 Ϯ 16% (SEM, n ϭ 10, P Ͻ 0.005) in ventricles and by 194 Ϯ 27% (SEM, n ϭ 4 pools from two to three mice, P Ͻ 0.001) in right atria.
Down-regulation of the ␣-MHC promoter-driven HA␣* q transgene occurs either transcriptionally or by increased RNA degradation, because the decrease in steady-state protein level was accompanied by a decrease in the steady-state level of the corresponding mRNA, as shown for ventricles in Fig. 3B . Expression of ␣-MHC itself may go down or be unchanged in response to cardiac hypertrophy (for example, refs. 19-21). In ␣* q 52 mice, the level of ␣-MHC mRNA was reduced by 10 weeks of age (Fig. 3B) , suggesting that the decrease in HA␣* q was a result of decreased ␣-MHC promoter activity.
Phospholipase C Activity in Hearts of ␣* q 52 Mice. In 2-weekold ␣* q 52 mice, basal PLC activity in the left and right atria was increased 9-to 10-fold over controls (Fig. 4) , confirming that HA␣* q stimulates PLC. A large phenotypic effect from such a small amount of transgene expression is what one would expect for a constitutively active protein. In contrast, there was only a minimal rise in ventricular PLC activity (Fig. 4) despite a similar level of HA␣* q expression in atria and ventricles (see Fig. 3A ). At 10 weeks, when HA␣* q protein was not detectable, PLC activity continued to be elevated in left and right atria (5-and 6.5-fold, respectively) and was elevated in ventricles (2-fold). We attribute the elevated basal PLC activity at 10 weeks to the up-regulation of endogenous ␣ q͞11 .
Cardiac Hypertrophy and Dilatation Proceed Despite the Down-Regulation of HA␣* q . As described above in detail (see paragraph on pathology), ␣* q 52 mice show only minimal pathology at 2 weeks when the transgene is expressed. The progression of the cardiomyopathy despite the disappearance of the transgene by 10 weeks is confirmed by the reexpression of fetal genes such as ␤-MHC and ANF in ventricles from ␣* q 52 mice (Fig. 3B) . The ␤-MHC mRNA was detectable at 4 weeks and increased further by 10 weeks. ANF mRNA was detectable at very low levels at 2 weeks. It reached high levels by 4 weeks and continued to be elevated by 10 weeks.
HA␣ * q -Induced Myocardial Hypertrophy Is Not Prevented by CsA. To test whether inhibition of calcineurin activity affects cardiac hypertrophy in ␣* q 52 mice, we analyzed two vehicletreated and two CsA-treated litters (each containing ␣* q 52 and wild-type mice). The treatment began at 17 or 18 days of age, when ␣* q 52 mice still express the HA␣* q protein but have not yet developed cardiac hypertrophy, and was carried out until they reached the age of 6.5 weeks, when they usually have developed hypertrophy. We chose a dose of 15 mg͞kg body weight (twice daily s.c.) since a higher dose of 25 mg͞kg used by Molkentin et al. (9) was lethal to most of our pups. The dose used in this study was sufficient to block calcineurin activity as shown by the lack of dephosphorylation of NFAT-1͞p upon incubation with increasing concentrations of the Ca 2ϩ ionophore, ionomycin, in spleen cells from CsA-treated mice compared with controls taken 5 hr after the last injection (Fig. 5) .
The effect of treatment with CsA on body weight, tibia length, and heart weights is shown for males in Table 2 . Treatment with CsA affected the growth rate of both wild-type and ␣* q 52 mice but had a much more profound effect on transgenic mice than on wild types. The body weight of CsA-treated ␣* q 52 mice was 31% less than vehicle-treated ␣* q 52 controls, while the CsA-treated wildtype mice lagged behind their vehicle-treated wild-type controls by only 10%. Although the transgenic mice had slightly shorter tibia lengths than wild-type controls, there was no significant difference in tibia length between vehicle-treated and CsAtreated animals.
The absolute weight of the ventricles from vehicle-treated 6.5-week-old ␣* q 52 mice was significantly larger than that of the wild type. The difference was reflected in increased VW͞BW ratio and ventricular weight͞tibia length (VW͞TL) ratio. On CsA treatment, the ventricular weights of both transgenes and wild types dropped significantly. The drop in ventricular weight was almost proportional to the body weight since the VW͞BW ratio did not change for ␣* q 52 mice and was only slightly reduced in wild types. Thus, the transgenic animals continued to have a high VW͞BW ratio after CsA treatment. However, the results calculated on the basis of tibia length were different. The VW͞TL ratio dropped significantly on CsA treatment both in wild-type and ␣ * q 52 mice and became essentially the same in both. Thus, by one measure (VW͞BW), CsA had no effect on the relative ventricular weight, but by another (VW͞TL), it made the ␣* q 52 ventricle indistinguishable from wild type. Because of the ambiguity in interpreting the results of the effect of CsA on ventricular weight, we used two other criteria to determine whether or not CsA affects the hypertrophy present in the transgenic animals: atrial weights and gene expression.
First, we considered the effect of CsA treatment on the atrial pathology. We do not know for certain whether the atrial pathology is a primary result of expression of the transgene, or whether it is secondary to a contractile defect in the ventricle. Both the right and left atria were massively enlarged in older ␣* q 52 mice. Some of the increase in weight of the left atrium is a result of the formation of organized thrombi, making analysis of left atrial weights harder to interpret. Nevertheless, the enlargement and thrombus formation appeared to be equal with or without CsA treatment (data not shown). The absolute weight of the right atrium (that did not contain thrombi) dropped slightly on CsA treatment, but the right AW͞BW ratio was not significantly different from vehicle-treated ␣* q 52 controls. The right AW͞TL FIG. 6 . Effect of CsA treatment on mRNA expression of hypertrophic markers. Northern blots of 5 g total RNA extracted from the ventricular apex from CsA-and vehicle-treated ␣* q52 and wild-type mice. For comparison, RNA extracted from 2-week-old ␣* q52 and wild-type mice is shown (only in A). The blots were probed with cDNA probes for ANF and GAPDH and oligonucleotide probes for ␣-MHC and ␤-MHC. Exposure times were 3 hr (ANF and GAPDH) and 17 hr (␣-MHC and ␤-MHC). Very little ANF mRNA was detectable in 2-week-old ␣* q52 when the film was overexposed for 13 hr (A). In addition to the data presented, two male CsA-treated ␣* q52 mice died before the end of the study (at 33 and 35 days of age) with increased heart weights (data not shown). The CsA-treated litters contained only four female ␣* q52, which had a similar phenotype as the males (data not shown). The four litters examined contained a total of 15 wild-type and 24 ␣* q52 mice, an unusual distribution. Most of the litters generated by heterozygote͞wild-type matings contain about 50% of each genotype (see, for example, Table 1 ratio dropped slightly but continued to be more than twice that of the wild type. We conclude that the atrial pathology continued on CsA treatment regardless of whether it is primary or a secondary reflection of ventricular dysfunction. Second, we assessed the development of hypertrophy by analyzing the mRNA expression of hypertrophic markers. Despite treatment with CsA, both ANF and ␤-MHC were reexpressed in ventricles from ␣* q 52 mice (Fig. 6A) . There was considerable variation in ANF and ␤-MHC mRNA levels. However, ANF mRNA levels were lower in CsA-treated compared with vehicletreated ␣* q 52 mice (see additional samples in Fig. 6B ). Nevertheless, they were always higher than in 2-week-old ␣* q 52 mice, where ANF mRNA was barely detectable (Fig. 6A) . The downregulation of ␣-MHC mRNA normally seen in ␣* q 52 mice was less apparent after CsA treatment (Fig. 6A) . Taken together, these data support the conclusion that CsA blunted some aspects of hypertrophy in ␣* q 52 mice, but did not prevent it.
DISCUSSION
Progression of Cardiac Pathology Despite Transgene DownRegulation. We have demonstrated that a transient modest expression of HA␣* q is sufficient to induce persistent changes that continue to drive cardiac pathology after the initiating stimulus is gone. In fact, at the time of transition to failure at 2 months or later, the HA␣* q protein is no longer detectable and its mRNA is greatly decreased. Since the expression of ␣-MHC itself is downregulated in hearts from ␣* q 52 mice, the decrease in HA␣* q mRNA is presumably a result of reduced ␣-MHC promoter activity. The ␣-MHC promoter activity might depend on the severity of hypertrophy, since the expression of ␣-MHC mRNA was reported to be unchanged in hypertrophied hearts of mice expressing unactivated ␣ q (6) or PKC␤ (10) . In several studies using the ␣-MHC promoter the level of transgene expression over time was not reported (3, 6, 10) . HA␣* q leads to increased PLC activity, but there is no linear relationship between the extent of activation of PLC (and presumably its downstream targets) and the development of hypertrophy. Despite a similar level of HA␣* q protein in atria and ventricles at 2 weeks, there is a large increase in basal PLC activity in atrial appendages, whereas in ventricles, basal PLC activity was only slightly increased. Possibly, subtle differences in HA␣* q expression may cause pronounced differences in PLC activity or the chambers may respond differently to a similar stimulus. It is not clear at present whether the atrial pathology is a consequence of transgene expression itself, or hemodynamic changes resulting from the ventricular abnormalities, or both. That the pathology in both atria and ventricles is very subtle at 2 weeks and progresses with time suggests an interplay of biochemical and hemodynamic factors.
Several factors might be responsible for the progression of the cardiomyopathy after the expression of HA␣* q has declined. Possibilities include (i) compensatory changes in the level of endogenous ␣ q/11 or other signaling molecules that sustain persistent differences in gene expression and (ii) compensation for early apoptosis leading to myocyte dropout during the time that the HA␣* q is expressed. Activated G␣ q has been shown to cause apoptosis in COS-7 or CHO cells (22) and in neonatal rat ventricular cardiomyocytes (23) . Further studies will be aimed at defining the relative importance of these and other mechanisms.
Cyclosporin A Blunts, but Does Not Prevent, Myocardial Hypertrophy in ␣* q 52 Mice. CsA inhibits the phosphatase calcineurin (9) . Since HA␣* q acts upstream of calcineurin and initiates additional pathways (such as activation of protein kinase C), we expected that CsA might blunt, but not eliminate, the phenotype. This is, indeed, the case. The observation that ANF and ␤-MHC are still reexpressed in the ventricles at high levels and the continued presence of atrial (and perhaps also ventricular) enlargement in CsA-treated ␣* q 52 mice demonstrate the CsA cannot prevent some aspects of myocardial hypertrophy in these animals. However, it does diminish some manifestations, such as the degree of ANF expression and ␣-MHC downregulation, and perhaps ventricular enlargement.
The dose of CsA used in this study was just sublethal and slightly lower than that given by Molkentin et al. (9) , but the same as used in (25) . It effectively blocked calcineurin in spleen cells. We propose that HA␣* q sets in motion pathways in addition to the ones leading to activation of calcineurin that are important in initiating or maintaining the pathology. Defining these additional pathways is a challenge for the future.
CONCLUSIONS
Compensatory changes in response to acute cardiac injury can lead to long-term pathology. We have now shown that transient expression of a single signaling molecule is sufficient to initiate a cascade of changes that lead to hypertrophy, dilatation, and eventually failure. Transgenic mice, such as the ones described here, can serve as informative model systems to identify primary triggers for hypertrophy, to establish the sequence of secondary changes, and to refine our understanding of the genetic basis for continued progression of the pathology after the primary trigger is no longer detectable.
